Arno Therapeutics and U.S. Army researchers to study antiviral effects of AR-12

Arno Therapeutics, Inc. said Wednesday that it has entered into a cooperative research and development agreement and material transfer agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study the antiviral effects of AR-12.

Arno Therapeutics, a Flemington, New Jersey-based biopharmaceutical firm that focuses on the development of therapeutic agents to treat patients with cancer and other potentially fatal diseases, and the Army research institute will study the antiviral effects of AR-12, an orally-available small molecule agent, and a variety of related compounds on Ebola and other viruses.

"This is an important step forward in the process of evaluating AR-12 and the other compounds in the AR-12 series against various microbial pathogens," Arno Therapeutics CEO Alex Zukiwski said. "We look forward to working with (the Army institute) to learn more about the potential activity of AR-12 and related compounds."

More information can be found at

Organizations in this Story

Arno Therapeutics, Inc

Want to get notified whenever we write about Arno Therapeutics, Inc ?
Next time we write about Arno Therapeutics, Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.